Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
1.
Adv Food Nutr Res ; 109: 160-184, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38777412

RESUMEN

Current global estimation suggests that about 10% of adults worldwide have diabetes, thus, various strategies are needed to address the issue, including dietary factors such as vitamin D. Various studies have suggested an inverse associations between vitamin D and the risks and pathogenesis of all forms of diabetes (type 1, type 2 and gestational diabetes). The underlying mechanism is not fully understood; however, the expression of vitamin D receptors in pancreatic beta cells suggests an important physiological role for vitamin D in beta cell function. Vitamin D deficiency may impair blood glucose control and decrease insulin sensitivity by reducing insulin secretion from beta cells. Many studies suggest that vitamin D intervention may be beneficial; however, there is inconclusive evidence of the effectiveness of vitamin D supplementation on reducing the risks or managing the pathogenesis of all forms of diabetes. Part of the pathogenesis of vitamin D for reducing diabetes is thought to be related to its impact on gut microbiota profile, via the suggested prebiotic properties of vitamin D.


Asunto(s)
Microbioma Gastrointestinal , Resistencia a la Insulina , Deficiencia de Vitamina D , Vitamina D , Humanos , Vitamina D/farmacología , Vitamina D/metabolismo , Microbioma Gastrointestinal/efectos de los fármacos , Diabetes Mellitus/prevención & control , Suplementos Dietéticos
2.
Front Nutr ; 10: 1167813, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37396123

RESUMEN

Introduction: With the prevalence of obesity increasing, many weight-loss programs were created to aid in combating the trend. The Weight Loss Clinic (WLC) was created to provide personalized support for lifestyle changes using a multidisciplinary team with medical oversight. This study evaluated the clinically-managed weight loss program at the Wellness Institute. Methods: This was a prospective evaluation of a newly established program between January 2019-August 2020. Participants who entered the weight loss program were approached to learn about the evaluation. A total of 41 participants were included. The primary outcomes included changes in body weight and achievement of more than 5% initial body weight loss. Outcome measures were collected pre-and post-program and the data was analyzed through paired t-tests on R studio. Results: Greater body weight-loss was seen in completers pre-COVID-19 compared to those who completed during the pandemic (Mean, ±SD; 7.51 ± 6.24 kg n = 13 p < 0.001 vs. 1.75 ± 4.43 kg n = 9, p = 0.02). Completers pre-COVID-19 demonstrated improvements in waist circumference, Framingham risk score, blood pressure, hemoglobin A1C, and body fat percentage. Conclusions and implications: Though the sample size was small to show definitve evidence, the results may suggest the program worked well prior to the pandemic but the pandemic created barriers to weight-loss for participants.

3.
Adv Food Nutr Res ; 96: 1-25, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34112350

RESUMEN

Calcium is well known to be integral to bone and muscle health, with deleterious effects such as osteoporosis associated with inadequate calcium intake. Recent studies have also highlighted the significant effects of calcium in extra-musculoskeletal functioning, including the cardiovascular system, obesity, and cancer. Calcium impacts the cardiovascular system as an antagonist associated with a reduction in hypertension, increase vasodilation, and improvement in blood vessel function when obtained in the diet as an organic source, through food. However, the inorganic source of calcium, found in supplements, may be negatively associated with the cardiovascular system due to plaque deposits and atherogenesis when taken in excess. Some studies suggest that calcium intake may impact obesity by regulation of adipogenesis and reducing fat deposits with resulting weight loss. The pathogenesis of calcium for reducing obesity is thought to be related in part to its impact on gut microbiota profile, with the suggestion that calcium may have prebiotic properties. Animal and some human studies propose that calcium may also have a role in cancer prevention and/or treatment due to its function in the cell proliferation process and the impact on hormonal regulation, and thus warrants more investigations in the human population. Some prospective and small clinical studies suggest that calcium may be beneficial for colorectal cancer. Overall, emerging research in various areas continues to highlight the essentiality of dietary calcium for functioning at the molecular and biochemical level toward improvement in health and some chronic disease conditions.


Asunto(s)
Sistema Cardiovascular , Neoplasias , Animales , Calcio de la Dieta , Suplementos Dietéticos , Humanos , Obesidad , Estudios Prospectivos
4.
Lipids ; 55(6): 569-584, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32557606

RESUMEN

Cardiovascular disease (CVD) is a leading cause of death worldwide. Elevated concentrations of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are major lipid biomarkers that contribute to the risk of CVD. Phytosterols well known for their cholesterol-lowering ability, are non-nutritive compounds that are naturally found in plant-based foods and can be classified into plant sterols and plant stanols. Numerous clinical trials demonstrated that 2 g phytosterols per day have LDL-C lowering efficacy ranges of 8-10%. Some observational studies also showed an inverse association between phytosterols and LDL-C reduction. Beyond the cholesterol-lowering beneficial effects of phytosterols, the association of phytosterols with CVD risk events such as coronary artery disease and premature atherosclerosis in sitosterolemia patients have also been reported. Furthermore, there is an increasing demand to determine the association of circulating phytosterols with vascular health biomarkers such as arterial stiffness biomarkers. Therefore, this review aims to examine the ability of phytosterols for CVD risk prevention by reviewing the current data that looks at the association between dietary phytosterols intake and serum lipid biomarkers, and the impact of circulating phytosterols level on vascular health biomarkers. The clinical studies in which the impact of phytosterols on vascular function is investigated show minor but beneficial phytosterols effects over vascular health. The aforementioned vascular health biomarkers are pulse wave velocity, augmentation index, and arterial blood pressure. The current review will serve to begin to address the research gap that exists between the association of dietary phytosterols with CVD risk biomarkers.


Asunto(s)
Enfermedades Cardiovasculares/dietoterapia , Enfermedades Cardiovasculares/prevención & control , Fitosteroles/sangre , Fitosteroles/farmacología , Biomarcadores/sangre , Enfermedades Cardiovasculares/sangre , Colesterol/sangre , Dieta , Alimentos , Humanos , Fitosteroles/clasificación
5.
BMJ Open ; 9(10): e023318, 2019 10 10.
Artículo en Inglés | MEDLINE | ID: mdl-31604781

RESUMEN

INTRODUCTION: Lifestyle factors, such as diet, physical activity and sleep, are associated with the development of many chronic diseases. The objective of The Manitoba Personalized Lifestyle Research study is to understand how these lifestyle factors interact with each other and with other factors, such as an individual's genetics and gut microbiome, to influence health. METHODS: An observational study of adults, with extensive phenotyping by objective health and lifestyle assessments, and retrospective assessment of early life experiences, with retrospective and prospective utilisation of secondary data from administrative health records. STUDY POPULATION: A planned non-random convenience sample of 840 Manitobans aged 30-46 recruited from the general population, stratified by sex (equal men and women), body mass index (BMI; 60% of participants with a BMI>25 kg/m2) and geography (25% from rural areas). These stratifications were selected based on Manitoba demographics. MEASUREMENTS: Lifestyle factors assessed will include dietary pattern, physical activity, cardiovascular fitness, and sleep. Factors such as medical history, socioeconomic status, alcohol and tobacco consumption, cognition, stress, anxiety, and early life experiences will also be documented. A maternal survey will be performed. Body composition and bone density will be measured by dual energy X-ray absorptiometry. Blood pressure, pulse wave velocity, and augmentation index will be measured on two consecutive days. Chronic disease risk biomarkers will be measured in blood and urine samples. DNA will be extracted for genetic analysis. A faecal sample will be collected for microbiome analysis. Participants may provide their Manitoba personal health information number to link their study data with administrative health records. ETHICS AND DISSEMINATION: Ethics approval has been obtained from the University of Manitoba Health Research Ethics Board (protocol # HS18951; 05/01/2016). Data analysis, release of results and publication of manuscripts are scheduled to start in early 2019. Additional information at www.TMPLR.ca. TRIAL REGISTRATION NUMBER: NCT03674957; Pre-results.


Asunto(s)
Conductas Relacionadas con la Salud , Estado de Salud , Estilo de Vida , Adulto , Estudios de Cohortes , Femenino , Humanos , Masculino , Manitoba , Registro Médico Coordinado , Persona de Mediana Edad
6.
J Steroid Biochem Mol Biol ; 190: 115-125, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30940596

RESUMEN

Serum concentrations of lathosterol, the plant sterols campesterol and sitosterol and the cholesterol metabolite 5α-cholestanol are widely used as surrogate markers of cholesterol synthesis and absorption, respectively. Increasing numbers of laboratories utilize a broad spectrum of well-established and recently developed methods for the determination of cholesterol and non-cholesterol sterols (NCS). In order to evaluate the quality of these measurements and to identify possible sources of analytical errors our group initiated the first international survey for cholesterol and NCS. The cholesterol and NCS survey was structured as a two-part survey which took place in the years 2013 and 2014. The first survey part was designed as descriptive, providing information about the variation of reported results from different laboratories. A set of two lyophilized pooled sera (A and B) was sent to twenty laboratories specialized in chromatographic lipid analysis. The different sterols were quantified either by gas chromatography-flame ionization detection, gas chromatography- or liquid chromatography-mass selective detection. The participants were requested to determine cholesterol and NCS concentrations in the provided samples as part of their normal laboratory routine. The second part was designed as interventional survey. Twenty-two laboratories agreed to participate and received again two different lyophilized pooled sera (C and D). In contrast to the first international survey, each participant received standard stock solutions with defined concentrations of cholesterol and NCS. The participants were requested to use diluted calibration solutions from the provided standard stock solutions for quantification of cholesterol and NCS. In both surveys, each laboratory used its own internal standard (5α-cholestane, epicoprostanol or deuterium labelled sterols). Main outcome of the survey was, that unacceptably high interlaboratory variations for cholesterol and NCS concentrations are reported, even when the individual laboratories used the same calibration material. We discuss different sources of errors and recommend all laboratories analysing cholesterol and NCS to participate in regular quality control programs.


Asunto(s)
Colesterol/sangre , Fitosteroles/sangre , Colestanol/sangre , Colesterol/análogos & derivados , Cromatografía de Gases/métodos , Cromatografía Liquida/métodos , Humanos , Sitoesteroles/sangre , Encuestas y Cuestionarios
7.
Nutr Res ; 60: 87-95, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30527263

RESUMEN

The purpose of this study was to evaluate the effectiveness of 3.0 g/d of omega-3 fatty acid (eicosapentaenoic acid and docosahexaenoic acid) supplementation combined with progressive resistance training to improve body composition and lower inflammatory cytokines in older men when compared to placebo and resistance training. We hypothesized that completing a 12-week omega-3 supplementation period along with whole body resistance exercise (3 times/wk) would result in a significantly greater improvement in lean tissue mass as well as a significant decrease in interleukin-6 and tumor necrosis factor-α when compared to placebo. A total of 23 older men (≥65 years old) were randomized to an omega-3 supplementation group (n = 11) or placebo group (n = 12), and all the participants completed the same whole body progressive resistance training program. Baseline and 12-week data collection included body composition, muscle strength, functional ability, and inflammatory cytokines. Results indicated a significant main effect for time (all P < .05) for percent body fat (-2.5%), lean tissue mass (+1.1%), lumbar bone mineral density (+1.1%), hip bone mineral content (+1.1%), chest press strength (+31%), leg press strength (+37%), timed-up-and-go (-6.6%), and 6-minute walk distance (+4.5%) from baseline to post 12 weeks. No significant effects were noted for the 2 inflammatory cytokines measured (P > .05). We conclude that progressive resistance training exercise is an excellent method to enhance parameters of body composition, skeletal muscle strength, and functional ability in older men, whereas omega-3 supplementation did nothing to enhance these parameters or influence inflammatory biomarkers.


Asunto(s)
Composición Corporal/efectos de los fármacos , Citocinas/sangre , Suplementos Dietéticos , Ácidos Grasos Omega-3/farmacología , Inflamación/sangre , Músculo Esquelético/efectos de los fármacos , Entrenamiento de Fuerza , Tejido Adiposo/metabolismo , Anciano , Biomarcadores/sangre , Compartimentos de Líquidos Corporales/metabolismo , Densidad Ósea/efectos de los fármacos , Ejercicio Físico , Humanos , Masculino , Fuerza Muscular/efectos de los fármacos , Músculo Esquelético/fisiología , Rendimiento Físico Funcional
8.
Nutr Rev ; 76(10): 725-746, 2018 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-30101294

RESUMEN

Current evidence indicates that foods with added plant sterols or stanols can lower serum levels of low-density lipoprotein cholesterol. This review summarizes the recent findings and deliberations of 31 experts in the field who participated in a scientific meeting in Winnipeg, Canada, on the health effects of plant sterols and stanols. Participants discussed issues including, but not limited to, the health benefits of plant sterols and stanols beyond cholesterol lowering, the role of plant sterols and stanols as adjuncts to diet and drugs, and the challenges involved in measuring plant sterols and stanols in biological samples. Variations in interindividual responses to plant sterols and stanols, as well as the personalization of lipid-lowering therapies, were addressed. Finally, the clinical aspects and treatment of sitosterolemia were reviewed. Although plant sterols and stanols continue to offer an efficacious and convenient dietary approach to cholesterol management, long-term clinical trials investigating the endpoints of cardiovascular disease are still lacking.


Asunto(s)
Anticolesterolemiantes/farmacología , Enfermedades Cardiovasculares/terapia , Dieta/métodos , Hipercolesterolemia/terapia , Enfermedades Intestinales/terapia , Errores Innatos del Metabolismo Lipídico/terapia , Fitosteroles/efectos adversos , Fitosteroles/farmacología , Canadá , Enfermedades Cardiovasculares/sangre , Colesterol/sangre , LDL-Colesterol/sangre , Congresos como Asunto , Humanos , Hipercolesterolemia/sangre , Enfermedades Intestinales/sangre , Errores Innatos del Metabolismo Lipídico/sangre , Fitosteroles/sangre
9.
Biochem Cell Biol ; 96(2): 222-229, 2018 04.
Artículo en Inglés | MEDLINE | ID: mdl-29091741

RESUMEN

Skeletal muscle is critical for mobility and many metabolic functions integral to survival and long-term health. Alcohol can affect skeletal muscle physiology and metabolism, which will have immediate and long-term consequences on health. While skeletal muscle abnormalities, including morphological, biochemical, and functional impairments, are well-documented in adults that excessively consume alcohol, there is a scarcity of information about the skeletal muscle in the offspring prenatally exposed to alcohol ("prenatal alcohol exposure"; PAE). This minireview examines the available studies addressing skeletal muscle abnormalities due to PAE. Growth restriction, fetal alcohol myopathy, and abnormalities in the neuromuscular system, which contribute to deficits in locomotion, are some direct, immediate consequences of PAE on skeletal muscle morphology and function. Long-term health consequences of PAE-related skeletal abnormalities include impaired glucose metabolism in the skeletal muscle, resulting in glucose intolerance and insulin resistance, leading to an increased risk of type 2 diabetes. In general, there is limited information on the morphological, biochemical, and functional features of skeletal abnormalities in PAE offspring. There is a need to understand how PAE affects muscle growth and function at the cellular level during early development to improve the immediate and long-term health of offspring suffering from PAE.


Asunto(s)
Trastornos del Espectro Alcohólico Fetal/metabolismo , Intolerancia a la Glucosa , Glucosa/metabolismo , Trastornos del Crecimiento/metabolismo , Músculo Esquelético/metabolismo , Enfermedades Neuromusculares/metabolismo , Animales , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/patología , Diabetes Mellitus Tipo 2/terapia , Trastornos del Espectro Alcohólico Fetal/patología , Trastornos del Espectro Alcohólico Fetal/terapia , Trastornos del Crecimiento/patología , Trastornos del Crecimiento/terapia , Humanos , Resistencia a la Insulina , Músculo Esquelético/anomalías , Músculo Esquelético/patología , Enfermedades Neuromusculares/patología , Enfermedades Neuromusculares/terapia
10.
Appl Physiol Nutr Metab ; 42(12): 1322-1329, 2017 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-28813611

RESUMEN

Early nutrition has critical influences on cardiovascular disease risk in adulthood. The study objectives were to evaluate the impact of low birth weight on fasting and postprandial lipid metabolism and endothelium function in Yucatan miniature pigs. Intrauterine growth-restricted (IUGR) piglets (n = 6; 3 days old, 0.73 ± 0.04 kg) were paired with normal-weight (NW) same-sex littermates (n = 6; 1.11 ± 0.05 kg) and fed milk replacer ad libitum for 4 weeks. Thereafter, all pigs were fed a standard diet ad libitum for 5 h/day with growth, intakes, and blood samples collected for 8 months. At 9 months old, pigs were surgically fitted with venous catheters and an oral fat tolerance test was performed. At 10 months old, pigs were killed and endothelium-dependent and -independent vasodilations of isolated coronary arteries were measured using wire-myographs. IUGR pigs demonstrated catch-up growth (P < 0.05) in body weight and abdominal circumference prior to sexual maturity (<7 months old) and had more (P < 0.05) subcutaneous fat at 10 months old compared with NW pigs. IUGR pigs had consistently higher fasting plasma triglyceride concentrations from 5 to 10 months old and higher liver triglyceride and total cholesterol concentrations at 10 months old (P < 0.05). The fat tolerance test revealed delayed postprandial triglyceride clearance in IUGR pigs, but no differences in plaque formation or vascular reactivity. To conclude, IUGR and early postnatal catch-up growth are associated with increased overall body fat deposition and altered triglyceride metabolism in adult Yucatan miniature swine.


Asunto(s)
Adiposidad/fisiología , Retardo del Crecimiento Fetal/veterinaria , Metabolismo de los Lípidos/fisiología , Porcinos/crecimiento & desarrollo , Animales , Animales Recién Nacidos , Dieta , Femenino , Masculino , Porcinos Enanos
11.
Curr Protein Pept Sci ; 18(12): 1273-1287, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28595527

RESUMEN

Creatine, a very popular supplement among athletic populations, is of growing interest for clinical applications. Since over 90% of creatine is stored in skeletal muscle, the effect of creatine supplementation on muscle metabolism is a widely studied area. While numerous studies over the past few decades have shown that creatine supplementation has many favorable effects on skeletal muscle physiology and metabolism, including enhancing muscle mass (growth/hypertrophy); the underlying mechanisms are poorly understood. This report reviews studies addressing the mechanisms of action of creatine supplementation on skeletal muscle growth/hypertrophy. Early research proposed that the osmotic effect of creatine supplementation serves as a cellular stressor (osmosensing) that acts as an anabolic stimulus for protein synthesis signal pathways. Other reports indicated that creatine directly affects muscle protein synthesis via modulations of components in the mammalian target of rapamycin (mTOR) pathway. Creatine may also directly affect the myogenic process (formation of muscle tissue), by altering secretions of myokines, such as myostatin and insulin-like growth factor-1, and expressions of myogenic regulatory factors, resulting in enhanced satellite cells mitotic activities and differentiation into myofiber. Overall, there is still no clear understanding of the mechanisms of action regarding how creatine affects muscle mass/growth, but current evidence suggests it may exert its effects through multiple approaches, with converging impacts on protein synthesis and myogenesis.


Asunto(s)
Creatina/administración & dosificación , Suplementos Dietéticos , Desarrollo de Músculos/efectos de los fármacos , Factores Reguladores Miogénicos/genética , Biosíntesis de Proteínas/efectos de los fármacos , Animales , Diferenciación Celular , Regulación de la Expresión Génica , Humanos , Factor I del Crecimiento Similar a la Insulina/genética , Factor I del Crecimiento Similar a la Insulina/metabolismo , Células Musculares/citología , Células Musculares/metabolismo , Desarrollo de Músculos/genética , Músculo Esquelético/citología , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/metabolismo , Factores Reguladores Miogénicos/agonistas , Factores Reguladores Miogénicos/metabolismo , Miostatina/genética , Miostatina/metabolismo , Biosíntesis de Proteínas/genética , Células Satélite del Músculo Esquelético/citología , Células Satélite del Músculo Esquelético/metabolismo , Transducción de Señal , Serina-Treonina Quinasas TOR/genética , Serina-Treonina Quinasas TOR/metabolismo
12.
J Pediatr ; 188: 198-204.e1, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28625503

RESUMEN

OBJECTIVES: To assess the association between biomarkers of thyroid status and 5α-stanols in patients with sitosterolemia treated with ezetimibe (EZE). STUDY DESIGN: Eight patients with sitosterolemia (16-56 years of age) were studied during 14 weeks off EZE therapy and 14 weeks on EZE (10 mg/day). Serum thyroid biomarkers (free triiodothyronine [FT3], free thyroxine [FT4], FT3/FT4 ratio, thyroid-stimulating hormone), 5α-stanols (sitostanol and cholestanol), and cholestanol precursors (total cholesterol and its synthesis marker lathosterol, and 7α-hydroxy-4-cholesten-3-one cholestenol) were measured at baseline and during the 14 weeks off EZE and on EZE. RESULTS: EZE increased FT3/FT4 (10% ± 4%; P = .02). EZE reduced plasma and red blood cells sitostanol (-38% ± 6% and -20% ± 4%; all P < .05) and cholestanol (-18% ± 6% and -13% ± 3%; all P < .05). The change in plasma cholestanol level on EZE inversely correlated with the change in FT3/FT4 (r = -0.86; P = .01). EZE lowered total cholesterol (P < .0001) and did not affect 7α-hydroxy-4-cholesten-3-one cholestanol. EZE increased (P < .0001) lathosterol initially, but the level was not sustained, resulting in similar levels at week 14 off EZE and on EZE. CONCLUSION: In patients with STSL, 5α-stanols levels might be associated with thyroid function. EZE reduces circulating 5α-stanols while increasing FT3/FT4, implying increased conversion of T4 to T3, thus possibly improving thyroid hormone status. TRIAL REGISTRATION: ClinicalTrials.govNCT01584206.


Asunto(s)
Anticolesterolemiantes/uso terapéutico , Ezetimiba/uso terapéutico , Hipercolesterolemia/sangre , Hipercolesterolemia/tratamiento farmacológico , Enfermedades Intestinales/sangre , Enfermedades Intestinales/tratamiento farmacológico , Errores Innatos del Metabolismo Lipídico/sangre , Errores Innatos del Metabolismo Lipídico/tratamiento farmacológico , Fitosteroles/efectos adversos , Adolescente , Adulto , Colestanol/sangre , Colestenonas/sangre , Colesterol/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fitosteroles/sangre , Sitoesteroles/sangre , Tirotropina/sangre , Tiroxina/sangre , Triyodotironina/sangre , Adulto Joven
13.
Atherosclerosis ; 260: 27-33, 2017 05.
Artículo en Inglés | MEDLINE | ID: mdl-28340366

RESUMEN

BACKGROUND AND AIMS: Sitosterolemia displays high plasma total sterols [high plant sterols (PS) + normal to high total cholesterol (TC)] with normal to moderately elevated low-density lipoprotein (LDL) levels. High LDL, intermediate-density lipoprotein (IDL) and very low-density lipoprotein (VLDL) particles, low high-density lipoprotein (HDL), and increased non-HDL and the ratios of TC and triglycerides (TG) to HDL can increase the risk for atherosclerosis. Ezetimibe (EZE) can reduce plasma PS and TC levels in sitosterolemia, but its effect on lipoprotein subclasses has not been previously reported. METHODS: Sitosterolemia patients (n = 8) were taken off EZE for 14 weeks (OFF EZE) and placed on EZE (10 mg/d) for 14 weeks (ON EZE). Serum lipids were measured enzymatically and lipoprotein subclasses were assessed by polyacrylamide gel electrophoresis. RESULTS: EZE reduced (p < 0.05) total sterols (-12.5 ± 4.1%) and LDL-sterol (-22.7 ± 5.7%) and its sterol mass of large VLDL (-24.4 ± 4.5%), VLDL remnants (-21.1 ± 7.9%) and large IDL (-22.4 ± 7.2%) compared to OFF EZE. EZE did not affect large LDL subclasses or mean LDL particle size (273.8 ± 0.6 vs. 274.6 ± 0.3 Å). EZE increased HDL-sterol (25.5 ± 8.0%, p = 0.008) including intermediate (34 ± 14%, p = 0.02) and large (33 ± 16%, p = 0.06) HDL. EZE reduced non-HDL-sterol (-21.8± 5.0%), total sterols/HDL (-28.2 ± 5.5%) and TG/HDL (-27.4 ± 6.5%, all p < 0.01). CONCLUSIONS: EZE improves VLDL and HDL subfraction distribution, thereby reducing the atherogenic lipid profile, thus providing potential clinical benefit in sitosterolemia beyond TC and PS reduction.


Asunto(s)
Ezetimiba/uso terapéutico , Hipercolesterolemia/tratamiento farmacológico , Enfermedades Intestinales/tratamiento farmacológico , Errores Innatos del Metabolismo Lipídico/tratamiento farmacológico , Lipoproteínas HDL/sangre , Lipoproteínas VLDL/sangre , Fitosteroles/efectos adversos , Adolescente , Adulto , Anticolesterolemiantes/uso terapéutico , HDL-Colesterol/sangre , Electroforesis en Gel de Poliacrilamida , Femenino , Humanos , Hipercolesterolemia/sangre , Enfermedades Intestinales/sangre , Errores Innatos del Metabolismo Lipídico/sangre , Lipoproteínas HDL/efectos de los fármacos , Lipoproteínas IDL/sangre , Lipoproteínas IDL/efectos de los fármacos , Lipoproteínas VLDL/efectos de los fármacos , Masculino , Persona de Mediana Edad , Fitosteroles/sangre , Resultado del Tratamiento , Adulto Joven
14.
J Phys Act Health ; 13(1): 111-8, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25831552

RESUMEN

OBJECTIVE: Our objective was to test the feasibility of sharing treadmill workstations among office workers to reduce time spent at low intensity and explore changes in health outcomes after a 3-month intervention. METHODS: Twenty-two office workers were asked to walk 2 hours per shift on a shared treadmill workstation for 3 months. Physical activity levels (ie, low, light, moderate, and vigorous), health-related measures (eg, sleep, blood pressure), treadmill usage information, and questions regarding participants' expectation and experiences were collected. RESULTS: Physical activity time at low intensity during workdays was reduced by 20.1% (P = .007) in the 71% of participants completing the study. Participants were 70% confident that they would keep using the treadmill workstations. Interestingly, systolic blood pressure, diastolic blood pressure, and sleep quality scores were significantly improved (P < .05). CONCLUSIONS: The use of such equipment to replace a few hours of sitting is feasible and might offer important health benefits.


Asunto(s)
Ejercicio Físico/fisiología , Prueba de Esfuerzo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Salud Laboral , Proyectos Piloto , Factores de Tiempo , Lugar de Trabajo
15.
J AOAC Int ; 98(3): 716-723, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25941971

RESUMEN

Phytosterolemia (sitosterolemia) is a rare autosomal recessive sterol storage disease caused by mutations in either of the adenosine triphosphate (ATP) binding cassette transporter genes; (ABC) G5 or ABCG8, leading to impaired elimination of plant sterols and stanols, with their increased accumulation in the blood and tissues. Thus the disease is characterized by substantially elevated serum plant sterols and stanols, with moderate to high plasma cholesterol levels, and increased risk of premature atherosclerosis. Hematologic abnormalities including macrothrombocytopenia, stomatocytosis and hemolysis are frequently observed in sitosterolemia patients. Currently, ezetimibe, a sterol absorption inhibitor, is used as the routine treatment for sitosterolemia, with reported improvement in plant sterol levels and hemolytic parameters. This review summarizes the research related to the health impact of plant sterols and stanols on sitosterolemia.


Asunto(s)
Hipercolesterolemia/sangre , Hipercolesterolemia/genética , Enfermedades Intestinales/sangre , Enfermedades Intestinales/genética , Errores Innatos del Metabolismo Lipídico/sangre , Errores Innatos del Metabolismo Lipídico/genética , Fitosteroles/efectos adversos , Fitosteroles/sangre , Plantas/química , Transportadoras de Casetes de Unión a ATP/genética , Humanos , Hipercolesterolemia/tratamiento farmacológico , Hipercolesterolemia/metabolismo , Enfermedades Intestinales/tratamiento farmacológico , Enfermedades Intestinales/metabolismo , Errores Innatos del Metabolismo Lipídico/tratamiento farmacológico , Errores Innatos del Metabolismo Lipídico/metabolismo , Mutación , Fitosteroles/genética , Fitosteroles/metabolismo
16.
J Pediatr ; 166(1): 125-31, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25444527

RESUMEN

OBJECTIVE: To assess if ezetimibe (EZE), a sterol-absorption inhibitor, improves platelet (PLT) count and size relative to its effect on plasma plant sterol (PS) in patients with sitosterolemia (STSL). STUDY DESIGN: Patients with STSL (5 males, 3 females, 16-56 years of age) receiving EZE intervention as part of their routine care participated in this study. EZE was discontinued for 14 weeks (off) and then resumed for another 14 weeks (on). Hematology variables along with plasma and red blood cells (RBC) PS and total cholesterol (TC) levels were measured at the end of each phase. RESULTS: EZE increased PLT count (23% ± 9%) and decreased mean PLT volume (MPV; 10% ± 3%, all P < .05). In patients off EZE, PLT counts inversely correlated (r = -0.96 and r = -0.91, all P < .01) with plasma and RBC PS to TC ratio (PS/TC), and MPV positively correlated (r = 0.91, P = .03 and r = 0.93, P = .02) with plasma and RBC PS/TC. EZE reduced plasma and RBC sitosterol (-35% ± 4% and -28% ± 3%), total PS (-37% ± 4% and -28% ± 3%, all P < .0001) levels, and PS/TC (-27% ± 4% and -28% ± 4%, P < .01). CONCLUSIONS: EZE reduces plasma and RBC PS levels, while increasing PLT count and decreasing MPV, and thereby may reduce the risk for bleeding in STSL. Plasma PS levels and ABCG5/ABCG8 genes should be analyzed in patients with unexplained hematologic abnormalities.


Asunto(s)
Anticolesterolemiantes/uso terapéutico , Azetidinas/uso terapéutico , Colesterol/sangre , Hipercolesterolemia/tratamiento farmacológico , Enfermedades Intestinales/tratamiento farmacológico , Errores Innatos del Metabolismo Lipídico/tratamiento farmacológico , Fitosteroles/efectos adversos , Fitosteroles/sangre , Recuento de Plaquetas , Adolescente , Adulto , Anticolesterolemiantes/administración & dosificación , Azetidinas/administración & dosificación , Canadá , Recuento de Eritrocitos , Ezetimiba , Femenino , Humanos , Hipercolesterolemia/sangre , Enfermedades Intestinales/sangre , Errores Innatos del Metabolismo Lipídico/sangre , Masculino , Persona de Mediana Edad , Proyectos Piloto , Resultado del Tratamiento , Estados Unidos , Adulto Joven
17.
Artículo en Inglés | MEDLINE | ID: mdl-24674990

RESUMEN

Non-cholesterol sterols (NCS) are used as surrogate markers of cholesterol metabolism which can be measured from a single blood sample. Cholesterol precursors are used as markers of endogenous cholesterol synthesis and plant sterols are used as markers of cholesterol absorption. However, most aspects of NCS analysis show wide variability among researchers within the area of biomedical research. This variability in methodology is a significant contributor to variation between reported NCS values and hampers the confidence in comparing NCS values across different research groups, as well as the ability to conduct meta-analyses. This paper summarizes the considerations and conclusions of a workshop where academic and industrial experts met to discuss NCS measurement. Highlighted is why each step in the analysis of NCS merits critical consideration, with the hopes of moving toward more standardized and comparable NCS analysis methodologies. Alkaline hydrolysis and liquid-liquid extraction of NCS followed by parallel detection on GC-FID and GC-MS is proposed as an ideal methodology for the bio-analysis of NCS. Furthermore the importance of cross-comparison or round robin testing between various groups who measure NCS is critical to the standardization of NCS measurement.


Asunto(s)
Cromatografía de Gases y Espectrometría de Masas/métodos , Extracción Líquido-Líquido/métodos , Esteroles/química , Fitosteroles/análisis , Fitosteroles/química , Fitosteroles/aislamiento & purificación , Esteroles/análisis , Esteroles/aislamiento & purificación
18.
Atherosclerosis ; 231(2): 291-9, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24267242

RESUMEN

Sitosterolemia (STSL) is a rare autosomal recessive disease, manifested by extremely elevated plant sterols (PS) in plasma and tissue, leading to xanthoma and premature atherosclerotic disease. Therapeutic approaches include limiting PS intake, interrupting enterohepatic circulation of bile acid using bile acid binding resins such as cholestyramine, and/or ileal bypass, and inhibiting intestinal sterol absorption by ezetimibe (EZE). The objective of this review is to evaluate sterol metabolism in STSL and the impact of the currently available treatments on sterol trafficking in this disease. The role of PS in initiation of xanthomas and premature atherosclerosis is also discussed. Blocking sterols absorption with EZE has revolutionized STSL patient treatment as it reduces circulating levels of non-cholesterol sterols in STSL. However, none of the available treatments including EZE have normalized plasma PS concentrations. Future studies are needed to: (i) explore where cholesterol and non-cholesterol sterols accumulate, (ii) assess to what extent these sterols in tissues can be mobilized after blocking their absorption, and (iii) define the factors governing sterol flux.


Asunto(s)
Aterosclerosis/tratamiento farmacológico , Azetidinas/farmacología , Colesterol/sangre , Hipercolesterolemia/metabolismo , Enfermedades Intestinales/metabolismo , Errores Innatos del Metabolismo Lipídico/metabolismo , Fitosteroles/efectos adversos , Esteroles/sangre , Xantomatosis/tratamiento farmacológico , Transportador de Casetes de Unión a ATP, Subfamilia G , Transportadoras de Casetes de Unión a ATP/metabolismo , Absorción , Colesterol/metabolismo , Progresión de la Enfermedad , Ezetimiba , Humanos , Hipercolesterolemia/sangre , Enfermedades Intestinales/sangre , Cinética , Errores Innatos del Metabolismo Lipídico/sangre , Proteínas de la Membrana/metabolismo , Proteínas de Transporte de Membrana , Fitosteroles/sangre , Fitosteroles/metabolismo , Sitoesteroles/sangre , Esterol O-Aciltransferasa/metabolismo , Esteroles/metabolismo , Esterol O-Aciltransferasa 2
19.
Comp Med ; 62(4): 282-90, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-23043781

RESUMEN

Radiotelemetry was used to evaluate diet-related elevation of blood pressure in adult Yucatan miniature swine. Systolic arterial blood pressure (SAP), diastolic atrial blood pressure (DAP), heart rate, and locomotor activity were assessed in 9- or 11-mo-old Yucatan miniature pigs fed a standard diet or a North American-type diet high in salt, fat, and sugar (HSFS). Compared with pigs fed standard diet, pigs fed HSFS diet showed markedly elevated SAP (132 ± 3 compared with 156 ± 6 mm Hg), whereas DAP was unchanged (92 ± 2 compared with 99 ± 5 mm Hg). In addition, all pigs were modestly sensitive to short-term changes in dietary salt, as indicated by a 6% to 7% response in blood pressure parameters. According to these data, the increase in SAP for pigs on the HSFS diet was too large to be explained by the NaCl content of the diet alone. We found no evidence of endothelial dysfunction, and the relaxation responses of isolated coronary arteries actually were enhanced in the HSFS group. In conclusion, in a Yucatan miniature pigs model chronically fed a HSFS diet, DAP did not increase, but SAP and pulse pressure appeared to be affected by high dietary levels of fat or sugar (or both).


Asunto(s)
Presión Sanguínea/efectos de los fármacos , Dieta Alta en Grasa/efectos adversos , Sacarosa en la Dieta/efectos adversos , Cloruro de Sodio Dietético/efectos adversos , Porcinos Enanos , Animales , Frecuencia Cardíaca/efectos de los fármacos , Locomoción/efectos de los fármacos , Porcinos , Telemetría/veterinaria
20.
Am J Clin Nutr ; 95(4): 837-44, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-22378727

RESUMEN

BACKGROUND: Plant sterol (PS) supplementation is increasingly accepted as a dietary strategy to lower plasma cholesterol concentrations. However, information is scarce about the effect of increased PS intake in potentially vulnerable groups, such as phytosterolemia heterozygotes (HET). OBJECTIVE: This study assessed the responsiveness of circulating PS and lipid concentrations and cholesterol kinetics (absorption and synthesis) to daily PS supplementation in HET (ABCG8 S107X mutation) compared with a healthy control cohort. DESIGN: A double-blind, randomized, crossover, placebo-controlled study was conducted in 10 HET and 15 control subjects. The participants had a mean (±SEM) age of 34 ± 2 y and a BMI (in kg/m²) of 29.9 ± 1.1 and consumed ∼1.6 g PS or placebo capsules daily with supper for 4 wk. Cholesterol absorption and synthesis were assessed by using [¹³C]cholesterol and deuterium oxide, respectively. RESULTS: Plasma LDL-cholesterol concentrations decreased (P = 0.006) in both groups after PS supplementation (HET: 2.73 ± 0.19 mmol/L; control: 3.11 ± 0.19 mmol/L) compared with placebo (HET: 3.12 ± 0.20 mmol/L; control: 3.50 ± 0.21 mmol/L), whereas PS concentrations (campesterol+ß-sitosterol) increased (P = 0.03) in both groups after PS supplementation (HET: 39.72 ± 6.05 µmol/L; control: 24.03 ± 1.65 µmol/L) compared with placebo (HET: 27.32 ± 3.80 µmol/L; control: 21.12 ± 2.05 µmol/L). Cholesterol absorption efficiency decreased (P = 0.010) by ∼22% and ∼17% and synthesis rates increased (P = 0.040) by ∼20% and ∼24% in the HET and control groups, respectively, in response to PS consumption compared with placebo. CONCLUSION: These data suggest that heterozygosity for the ABCG8 S107X mutation does not influence the action of dietary PS on circulating cholesterol concentrations but may affect sterol absorption.


Asunto(s)
Transportadoras de Casetes de Unión a ATP/genética , Colesterol/metabolismo , Suplementos Dietéticos , Hipercolesterolemia/dietoterapia , Enfermedades Intestinales/dietoterapia , Errores Innatos del Metabolismo Lipídico/dietoterapia , Lípidos/sangre , Fitosteroles/uso terapéutico , Transportador de Casete de Unión a ATP, Subfamilia G, Miembro 8 , Transportadoras de Casetes de Unión a ATP/química , Adolescente , Adulto , Anciano , Sustitución de Aminoácidos , Colesterol/biosíntesis , Colesterol/sangre , Estudios de Cohortes , Estudios Cruzados , Método Doble Ciego , Femenino , Heterocigoto , Humanos , Hipercolesterolemia/etiología , Hipercolesterolemia/genética , Hipercolesterolemia/metabolismo , Hipercolesterolemia/fisiopatología , Hipercolesterolemia/prevención & control , Absorción Intestinal , Enfermedades Intestinales/genética , Enfermedades Intestinales/metabolismo , Enfermedades Intestinales/fisiopatología , Cinética , Errores Innatos del Metabolismo Lipídico/genética , Errores Innatos del Metabolismo Lipídico/metabolismo , Errores Innatos del Metabolismo Lipídico/fisiopatología , Masculino , Persona de Mediana Edad , Proteínas Mutantes/química , Proteínas Mutantes/genética , Fitosteroles/efectos adversos , Fitosteroles/sangre , Fitosteroles/genética , Fitosteroles/metabolismo , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...